Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7,690 | $7,876 | $5,729 | $1,260 |
| % Growth | -2.4% | 37.5% | 354.7% | – |
| Cost of Goods Sold | $0 | $61,542 | $73,123 | $75,655 |
| Gross Profit | $7,690 | -$53,666 | -$67,394 | -$74,395 |
| % Margin | 100% | -681.4% | -1,176.4% | -5,904.4% |
| R&D Expenses | $57,469 | $61,542 | $73,123 | $75,655 |
| G&A Expenses | $18,457 | $22,530 | $22,927 | $18,393 |
| SG&A Expenses | $18,457 | $22,530 | $22,927 | $18,393 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4,812 | -$61,542 | -$73,123 | -$75,655 |
| Operating Expenses | $80,738 | $22,530 | $22,927 | $18,393 |
| Operating Income | -$73,048 | -$76,196 | -$90,321 | -$92,788 |
| % Margin | -949.9% | -967.4% | -1,576.6% | -7,364.1% |
| Other Income/Exp. Net | $9,930 | $6,999 | $2,223 | -$5,803 |
| Pre-Tax Income | -$63,118 | -$69,197 | -$88,098 | -$98,591 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$63,118 | -$69,197 | -$88,098 | -$98,591 |
| % Margin | -820.8% | -878.6% | -1,537.8% | -7,824.7% |
| EPS | -1.65 | -1.83 | -2.3 | -2.79 |
| % Growth | 9.8% | 20.4% | 17.6% | – |
| EPS Diluted | -1.65 | -1.83 | -2.3 | -2.79 |
| Weighted Avg Shares Out | 38,184 | 37,812 | 37,358 | 37,400 |
| Weighted Avg Shares Out Dil | 38,184 | 37,812 | 37,358 | 37,400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,255 | $6,999 | $2,223 | $281 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,781 | $1,854 | $1,666 | $1,193 |
| EBITDA | -$66,455 | -$74,342 | -$88,655 | -$91,595 |
| % Margin | -864.2% | -943.9% | -1,547.5% | -7,269.4% |